Literally none of this matters. AlloVir and Marker went their separate directions. Period. They won't be combining forces anytime soon. Especially since AlloVir is part of Elevate Bio. The CEO of AlloVir is also the CFO and co-founder of Elevate. If you insist on speculating, Marker has a better shot at working out a deal with Elevate than AlloVir. And that is also probably not going to happen because part of Elevate's "platform" is providing a manufacturing facility that all of their portfolio companies have access to. Since this is something Marker does not need a deal between the two is probably a long shot.
News 
Market Data 
Discover 
